CD103, also known as integrin αE, is a cell-surface protein that anchors immune cells to epithelial tissues by binding a molecule called E-cadherin on the surface of epithelial cells. That anchoring function makes CD103 one of the most reliable markers for identifying immune cells that have taken up permanent residence in tissues rather than circulating through the bloodstream. Its significance extends well beyond a simple address label, though: CD103 actively shapes how T cells kill tumor targets, how dendritic cells present antigens, and how certain regulatory cells suppress immune responses. Across oncology, infectious disease, autoimmunity, and diagnostic pathology, CD103 keeps turning up as a molecule that matters far more than its quiet name suggests.
How CD103 Keeps Immune Cells in Place
Epithelial surfaces line the skin, gut, lungs, and many other organs. The cells forming those surfaces display E-cadherin on their outer membranes. CD103 on a T cell grabs E-cadherin on an epithelial cell, physically tethering the immune cell to the tissue. This binding is what allows certain immune cells to resist the pull of lymphatic drainage and stay put for months or years in the skin, the intestinal lining, or a tumor bed.
The signal that tells a T cell to start making CD103 is TGF-β, a cytokine abundant in mucosal and epithelial environments. When a T cell arrives in, say, the gut lining, local TGF-β drives CD103 expression on that cell’s surface, which then locks the cell into the tissue. Without either TGF-β signaling or CD103 itself, T cells fail to accumulate properly in the intestinal epithelium and other barrier tissues.1Frontiers in Immunology. Niches for the Long-Term Maintenance of Tissue-Resident Memory T Cells This TGF-β–CD103 axis is the central mechanism behind tissue-resident memory T cell development and has become one of the most studied pathways in mucosal immunology.2PubMed Central. TGF-β: Many Paths to CD103+ CD8 T Cell Residency
CD103 as a Hallmark of Tissue-Resident Memory T Cells
Tissue-resident memory T cells, often abbreviated TRM, are a specialized subset of memory T cells that patrol specific organs without recirculating through the blood. They are your body’s locally stationed first responders, already positioned at the sites where infections or cancers are most likely to appear. CD103 is one of the defining markers of these cells, particularly for CD8+ TRM cells in epithelial tissues. When researchers isolate TRM cells from lung tumors, for instance, those cells reliably express CD103 alongside other residency markers and frequently co-express checkpoint receptors like PD-1 and Tim-3.3The Journal of Immunology. CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The fact that these cells co-express checkpoint receptors does not necessarily mean they are exhausted and useless. It often reflects a state of chronic antigen engagement: the cells have been fighting, and their brakes are partially on. That detail becomes clinically important when checkpoint immunotherapy enters the picture, as we will see shortly.
CD103 in Tumor Killing
CD103 does more than simply hold a T cell near a tumor cell. It actively participates in forming the immune synapse, the tight cell-to-cell contact through which a cytotoxic T cell delivers its lethal payload. When CD103 on a tumor-infiltrating T cell binds E-cadherin on an epithelial cancer cell, it triggers polarization of lytic granules containing granzyme B and the cytokine IFN-γ toward the target. In one study, roughly 60% of conjugates formed between CD103+ T cells and tumor cells showed this polarization of killing machinery. When researchers silenced E-cadherin on the tumor cells, the physical contacts still formed, but the polarization of granules and cytokines collapsed, and killing efficiency dropped.4Cancer Research. CD103 or LFA-1 Engagement at the Immune Synapse between Cytotoxic T Cells and Tumor Cells Promotes Maturation and Regulates T-cell Effector Functions
Downstream of the E-cadherin binding event, the intracellular tail of CD103 recruits a scaffolding protein called paxillin, which helps organize the cytoskeletal rearrangements needed for a mature immune synapse. This recruitment depends on phosphorylation of a specific residue inside the CD103 molecule. Disrupting that phosphorylation site blocks both CD103 clustering at the contact zone and the downstream signaling that powers the kill.5Cancer Research. Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8+ Resident Memory T Cells in Tumors In short, CD103 is not a bystander marker on these cells. It is mechanistically required for efficient tumor cell killing at epithelial surfaces.6Frontiers in Immunology. The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin
What CD103+ Immune Cells Mean for Cancer Prognosis
Across multiple tumor types, having more CD103+ immune cells inside the tumor tends to correlate with better outcomes. A systematic review and meta-analysis of solid tumors found that tumors positive for CD103+ immune cells were associated with better overall survival, disease-free survival, and disease-specific survival.7PubMed Central. Prognostic significance of CD103+ immune cells in solid tumor: a systemic review and meta-analysis In melanoma patients who had not received immunotherapy, those with higher counts of CD103+ tumor-resident CD8+ T cells had a five-year melanoma-specific survival around 50%, compared with roughly 20% in patients with lower counts.8Clinical Cancer Research. CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
In triple-negative breast cancer, the picture gets more nuanced. Researchers found that it was not just the number of CD103+ T cells that mattered, but where they sat and how closely they interacted with other immune cells. Patients whose CD103+ T cells formed strong spatial interactions with neighboring immune cells in the peripheral region of the tumor after chemotherapy had significantly better recurrence-free and overall survival than those whose CD103+ cells were more isolated.9Cancer Research and Treatment. Spatial Interactions of CD103+ Tissue-Resident Memory T Cells in the Tumor Periphery Are Associated with Clinical Outcomes in Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy The spatial arrangement provided stronger prognostic information than cell density alone.
The Complication of CD103+ Regulatory T Cells
Not every CD103+ cell inside a tumor is a killer. CD103 also marks a subset of regulatory T cells (Tregs) that infiltrate tumors, and these cells do the opposite of what CD103+ cytotoxic T cells do. They suppress immune responses. CD103+ Tregs were found to suppress effector T cell activation more potently than Tregs lacking CD103.10PubMed. CD103 is a hallmark of tumor-infiltrating regulatory T cells
In glioblastoma, this becomes a serious barrier to treatment. Researchers found that CD103+ Tregs accumulated in the tumor microenvironment after combined radiation and checkpoint blockade therapy. These cells were substantially more immunosuppressive than the conventional CD25+ Tregs, driving nearby CD8+ T cells into a more exhausted and less functional state.11Nature Cancer. CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma This means CD103 positivity in a tumor sample can cut both ways: it might reflect robust anti-tumor immunity, or it might reflect potent immunosuppression, depending on which cell types are carrying the marker. Distinguishing CD103+ killers from CD103+ suppressors requires looking at additional markers beyond CD103 alone.
Glioblastoma studies have also shown that the combination of CD103 with exhaustion markers tells a different story. Patients with low numbers of CD8+ T cells co-expressing CD103, PD-1, and Tim-3 had longer overall survival, suggesting that when TRM cells have accumulated too many exhaustion markers, their prognostic benefit flips.12PubMed. CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis
Predicting Who Will Respond to Immunotherapy
The presence of CD103+ CD8+ TRM cells inside tumors can predict whether a patient will respond to checkpoint blockade with anti-PD-1 or anti-PD-L1 therapy. Patients who respond to these treatments tend to be those with an ongoing anti-tumor T cell response already in place, and CD103 expression is one of the clearest indicators of that pre-existing response.13Journal for ImmunoTherapy of Cancer. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
In melanoma patients treated with anti-PD-1 antibodies, researchers observed that CD103+ tumor-resident CD8+ T cells expanded significantly early in treatment. Among those with early biopsies available, responders showed a trend toward greater expansion of these cells compared with non-responders, suggesting a threshold of CD103+ TRM numbers might be necessary for treatment to work.8Clinical Cancer Research. CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment This makes CD103 measurement a potential biomarker for patient selection in immunotherapy, though it has not yet become a standard clinical test.
CD103+ Dendritic Cells and Antigen Presentation
CD103 is not restricted to T cells. A specialized subset of dendritic cells in peripheral tissues, particularly in the skin and gut, also expresses CD103. These dendritic cells play a unique role: they are the migratory subset most efficient at cross-presenting antigens to CD8+ T cells. Cross-presentation is the process by which a cell takes up external material, such as viral proteins or debris from dead tumor cells, and presents it in a way that activates killer T cells.
In the skin, researchers found that only the CD103+ dendritic cell subset efficiently presented herpes simplex virus antigens to naive CD8+ T cells, even though all dendritic cell subsets could present the same antigens to CD4+ helper T cells. The CD103+ subset was also the best at cross-presenting skin-derived self-antigens.14PubMed. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells This specialization makes CD103+ dendritic cells critical bridges between innate and adaptive immunity at barrier tissues, and their absence or dysfunction can impair the initiation of cytotoxic immune responses against viruses and tumors alike.
CD103 on Natural Killer Cells
T cells and dendritic cells are not the only cells that wear CD103. Natural killer (NK) cells in epithelial tissues express it too, and this marks them as tissue-resident NK cells. In the human intestine, epithelial NK cells show very high CD103 expression, with a median of around 90% in infants and 93% in adults.15Nature Communications. Tissue-resident Eomes+ NK cells are the major innate lymphoid cell population in human infant intestine These tissue-resident NK cells appear to be functionally significant in tumor settings as well. In human lung tumors, tissue-resident NK cells accumulate preferentially toward the center of the tumor and show higher levels of cytotoxic molecules like granzymes there.16PubMed Central. Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8(+) T cells towards the center of human lung tumors
In head and neck cancer, a related population of CD49a+CD103+ cells resembling a particular innate lymphoid cell type was identified as the NK cell phenotype with the greatest anti-tumor activity. Their differentiation required both the cytokine IL-15 and direct contact with tumor cells.17PubMed Central. Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment So CD103 appears to mark the most tissue-committed, functionally potent members of multiple immune cell lineages, not just T cells.
Diagnosing Hairy Cell Leukemia
Outside the world of solid tumors, CD103 has an established role in diagnostic pathology. It is one of the standard markers used to identify hairy cell leukemia (HCL), a rare blood cancer. In flow cytometry panels, CD103 was found to be 100% sensitive and 100% specific for distinguishing HCL and its variant form from other low-grade B cell cancers like mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and splenic marginal zone lymphoma.18PubMed Central. Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia: Usefulness of CD123 and CD103 in the Diagnosis of Mature B-Cell Lymphoproliferative Disorders Combined with markers like CD25 and CD123, CD103 helps pathologists distinguish classic HCL from its variant form, which shares CD103 positivity but differs in CD25 and CD123 patterns.19PubMed Central. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria This diagnostic application is one of the most clear-cut clinical uses of CD103 today.
Autoimmune Skin Disease and Recurring Inflammation
The same TRM cells marked by CD103 that protect against infections and tumors can drive autoimmune disease when they target the body’s own tissues. In the skin, CD103+ TRM cells have been implicated in the recurrence of psoriasis, vitiligo, and fixed drug eruption.20PubMed Central. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders These cells persist in clinically healed skin long after visible lesions have cleared, and they can reignite disease when reactivated.
Interestingly, the marker CD49a separates CD103+ TRM cells into functionally distinct populations in skin disease. CD49a-positive CD103+ TRM cells produce IFN-γ and drive vitiligo, an autoimmune condition that destroys melanocytes. CD49a-negative CD103+ TRM cells produce IL-17 instead and drive psoriasis.21Frontiers in Immunology. Resident Memory T Cells in Autoimmune Skin Diseases This distinction matters clinically: anti-IL-17 drugs are highly effective in psoriasis, and the identification of CD49a-negative IL-17-producing TRM cells as the culprit helps explain why. It also illustrates a recurring theme with CD103: the marker identifies tissue-resident cells, but you need additional markers to determine what those cells are actually doing.
Gut Immunity, Inflammatory Bowel Disease, and Graft-Versus-Host Disease
The intestinal epithelium is one of the tissues where CD103 is most functionally important. In patients with inflammatory bowel disease (IBD), active inflammation is associated with decreased percentages of both CD103+ CD4+ and CD103+ CD8+ T cell subsets in colon and ileum biopsies. These populations recover during remission to levels comparable with healthy controls.22PubMed Central. Intestinal CD103+ CD4+ and CD103+ CD8+ T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up Similarly, CD103+ dendritic cells in the gut, which normally help maintain immune tolerance to food antigens and commensal bacteria, are lost during colitis.23PubMed Central. Loss of CD103+ intestinal dendritic cells during colonic inflammation The loss of these tolerogenic dendritic cells may contribute to the cycle of inflammation that defines IBD.
CD103 also plays a pivotal role in graft-versus-host disease (GVHD), a common and sometimes fatal complication of bone marrow transplantation. In GVHD, donor T cells attack the recipient’s tissues, and the gut is a primary target. Researchers demonstrated that donor CD8+ T cells express CD103 as they invade the host intestinal epithelium, and that CD103-deficient donor T cells were markedly less able to cause intestinal GVHD or related mortality.24PubMed Central. TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease This finding underscores how the tissue-homing function of CD103 can be destructive when the immune cells carrying it are directed against the wrong target.
Therapeutic Approaches Targeting CD103 Biology
The dual nature of CD103, helpful in anti-tumor immunity but harmful in autoimmunity and GVHD, has led to therapeutic strategies running in opposite directions. In oncology, the goal is to increase CD103+ TRM cells inside tumors. One emerging approach involves engineering CAR-T cells (chimeric antigen receptor T cells) to express CD103 and adopt a tissue-resident memory phenotype. Researchers showed that exposing peripheral T cells to TGF-β during manufacturing induces CD103 upregulation and promotes a TRM-like state. These engineered CAR-TRM cells showed enhanced efficacy against tumors compared with conventional CAR-T cells, and depleting the CD103+ fraction from the product partially reversed the benefit, confirming that the residency phenotype was a key contributor to their potency.25PubMed Central. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors
On the other side, in inflammatory bowel disease, the goal is to block the immune cells that use CD103’s partner integrin β7 to traffic into the gut. Etrolizumab is a monoclonal antibody targeting the β7 subunit shared by both α4β7 and αEβ7 (the CD103-containing integrin). By blocking β7, it aims to reduce both the migration of new immune cells into the gut and the retention of CD103+ cells already there.26PubMed. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis Its phase III clinical program enrolled over 3,000 patients with ulcerative colitis and Crohn’s disease, making it one of the largest IBD trial programs conducted.27PubMed Central. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
CD103+ TRM Cells in Respiratory Infections
One of the most practically relevant roles of CD103+ TRM cells is in fighting respiratory viruses. In the context of influenza, CD103+ TRM cells stationed in the lungs can respond rapidly upon reinfection, producing cytokines and directly killing virus-infected cells before the infection can spread deeply.28ImmunoHorizons. Influenza-Induced CD103+ T Resident Memory Cells Exhibit Enhanced Functional Avidity over CD103− Memory T Cells in the Mediastinal Lymph Node Because these cells target conserved viral proteins rather than the surface proteins that mutate between flu strains, they can provide cross-protective immunity against different subtypes of influenza, something circulating antibodies alone often cannot do.
An even more striking finding comes from the upper respiratory tract. Nasal TRM cells formed after upper airway immunization were able to block influenza virus transmission from the nose to the lungs, preventing severe pulmonary disease entirely. Unlike TRM cells in the lung itself, which decay relatively quickly and depend on local antigen and TGF-β signaling for their maintenance, nasal TRM cells developed independently of those signals and persisted with minimal decay.29PubMed. Resident memory CD8(+) T cells in the upper respiratory tract prevent pulmonary influenza virus infection This has implications for vaccine design: intranasal vaccines that establish CD103+ TRM cells in the nasal passages could provide a front-line defense that injectable vaccines, which primarily generate circulating immunity, cannot match.
Why Context Always Matters with CD103
A recurring theme across all these settings is that CD103 positivity alone does not tell you whether a cell is friend or foe. CD103+ cytotoxic T cells kill tumors. CD103+ regulatory T cells suppress anti-tumor immunity. CD103+ TRM cells in the skin protect against herpes reactivation but also drive psoriasis flares. CD103+ dendritic cells maintain gut tolerance under healthy conditions and cross-present viral antigens during infection. And CD103+ donor T cells destroy the intestinal epithelium in graft-versus-host disease. The molecule’s biological function, tethering immune cells to epithelial surfaces, is constant. What varies, and what determines whether the outcome is protective or pathological, is the identity and programming of the cell carrying it. That is why researchers studying CD103 rarely look at it in isolation. They pair it with markers like CD8, CD4, FoxP3, CD49a, PD-1, Tim-3, and others to decode what a given CD103+ population is actually doing in a particular tissue at a particular time. In non-small cell lung cancer, for instance, checkpoint marker expression on the CD103+ CD4+ T cell subset correlated strongly with circulating tumor cell numbers, a finding that required looking at both CD103 and the checkpoint markers together to be interpretable.30Translational Oncology. Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: Checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells